



## **Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September**

September 3, 2020

NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September:

### **Baird 2020 Global Healthcare Conference**

**Date:** Thursday, September 10

**Time:** 9:40 a.m. ET

### **H.C. Wainwright & Co. 22<sup>nd</sup> Annual Global Investor Conference**

**Date:** Tuesday, September 15

**Time:** 12:30 p.m. ET

Live audio webcasts of the presentations will be available under "Events and Presentations" in the Investors section of the Company's website at [www.allenapharma.com](http://www.allenapharma.com). Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

### **About Allena Pharmaceuticals**

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, relxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

### **Investor Contact**

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

### **Media Contact**

Adam Daley

Berry & Company Public Relations

212-253-8881

[adaley@berrypr.com](mailto:adaley@berrypr.com)



Source: Allena Pharmaceuticals, Inc.